Wolf Haldenstein Adler Freeman & Herz LLP
NEW YORK, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of all persons or entities that purchased the common stock of Energy Recovery, Inc. ("Energy Recovery" or the "Company") (Nasdaq:ERII) between March 14, 2012 and January 13, 2015, inclusive (the "Class Period"). Shareholders with significant losses are encouraged to contact us immediately at (800) 575-0735 or email
Brower Piven, A Professional Corporation
STEVENSON, Md., Jan. 30, 2015 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of InvenSense, Inc. ("InvenSense" or the "Company") (NYSE:INVN) common stock during the period between July 29, 2014 and October 28, 2014, inclusive (the "Class Period"). Investors who wish to become proactively involved in the litigation have until March 9, 2015 to seek appointment as lead plaintiff.
Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER
SAN DIEGO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Zohydro
Federal Home Loan Bank of San Francisco
FHLBank San Francisco Releases December 2014 Cost of Funds Index
SAN FRANCISCO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- The Federal Home Loan Bank of San Francisco (Bank) announced January 30, 2015, that the 11
Chimerix Focusing Efforts on CMV and Adenovirus Pivotal Trials
DURHAM, N.C., Jan. 30, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that after discussion with the U.S. Food and Drug Administration, the company is ceasing further participation in all current and future clinical studies of brincidofovir for Ebola Virus Disease (EVD), including the study announced in December in Liberia sponsored by investigators at the University of Oxford and the supportive Phase 2 study of brincidofovir for EVD, Study 205.
SAN FRANCISCO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Pillow Homes, a technology-driven hospitality company for short-term rentals, is helping homeowners to understand the new SF regulations and maximize income from renting their home.
Guggenheim Investments Exchange-Traded Funds Declare Monthly Distributions
NEW YORK, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Guggenheim Investments, the investment management division of Guggenheim Partners, today announced that the following Guggenheim exchange-traded funds ("ETFs") have declared distributions. The table below summarizes the distribution for each ETF.
New Resource Bank Reports Fourth Quarter 2014 Financial Results
SAN FRANCISCO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- New Resource Bank (OTCBB:NWBN) has announced unaudited financial results for the quarter ended December 31, 2014.
Famous Dave's Fourth Quarter 2014 Earnings Release and Conference Call
MINNEAPOLIS, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Famous Dave's of America, Inc. (Nasdaq:DAVE) ("Famous Dave's") will announce its Fourth Quarter 2014 earnings at 7:00 a.m., Central Time on Thursday, February 19, 2015. The company will host a conference call on February 19, 2015 at 7:30 a.m., Central Time, to discuss its financial results. A live web-cast of the discussion will be available through the "Investor Relations" section of Famous Dave's web site at
BankFinancial Corporation Announces 2014 Financial Results
BURR RIDGE, Ill., Jan. 30, 2015 (GLOBE NEWSWIRE) -- BankFinancial Corporation (Nasdaq:BFIN) (the "Company") announced today the Company recorded net income of $40.6 million and earnings per share of common stock of $2.01 for the year ended December 31, 2014. The Company's pre-tax, pre-provision income was $10.8 million in 2014, compared to $5.5 million in 2013.
